Page 1 of 2

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 028622/0102 09/673,735 APPLICANT INFORMATION DISCLOSURE CITATION Bernd DORKEN et al. **GROUP ART UNIT FILING DATE** (Use several sheets if necessary) December 27, 2000 Unassigned **U.S. PATENT DOCUMENTS** FILING DATE DOCUMENT SUB-**EXAMINER** DATE CLASS · NAME REF IF INITIAL **CLASS** NUMBER **APPROPRIATE FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT SUB-DATE COUNTRY **CLASS** REF NUMBER **CLASS** YES NO 195 31 348 2/27/97 Fed. Republic of Germany Х **A1** 0 505 908 9/30/92 Europe A2 7/11/91 **WIPO** 91/09968 100 A3i 95/11922 5/4/95 WIPO A4_ WIPO 96/36360 11/21/96 A5 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) H. Bohlen et al., "TREATMENT OF EB-VIRUS INDUCED B-CELL LCL IN SCID-HU MICE USING CD3XCD19 A6L BISPECIFIC AND CD28 ANTIBODIES.", Proceedings of the American Association for Cancer Research, vol. 35, March, 1994, pg. 510, XP-002076122, abstract. Jan De Jonge et al., "Bispecific antibody treatment of murine B cell lymphoma.", Cancer Immunology A7 Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997 Sergey M. Kipriyanov et al., "BISPECIFIC CD3 X CD19 DIABODY FOR T-CELL-MEDIATED LYSIS OF MALIGNANT HUMAN B CELLS.", International Journal of Cancer, vol. 77, August 31, 1998, pp. 763-772, XP-A8 002115487, Wiley-Liss, Inc., 1998 P. Kufer et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. Α9 193-197, XP-002076121, Springer-Verlag, 1997 Anja Schroder et al., "A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCED RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED HUMAN T CELLS.", 40th A10 Annual Meeting Of The American Society Of Hematology Miami Beach, Florida, December 4-8, 1998, XP-002115457, abstract. **EXAMINER** DATE CONSIDERED EXAMINER: //nitial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Page 2 of 2

Form PTO-1	449	U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.	
(MODIFIED)		PATENT AND TRADEMARK OFFICE	028622/0102	09/673,735	
			APPLICANT		
INFORMATION DISCLOSURE CITATION			Bernd DORKEN et al.		
			FILING DATE	GROUP ART UNIT	
,	(Use s	everal sheets if necessary)	December 27, 2000	Unassigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
- P	A11 C	"National Cancer Institute Sponsored Stu- Description of a Working Formulation for	dy of Classifications of Non-Hodgkin's Clinical Usage.", Cancer, vol. 49, pp. 2	Lymphomas, Summary and 112-2135, 1982, (Exhibit 1)	
	A12	Harald Stein et al., "Die neue WHO-Klassifikation der malignen Lymphome.", Deutsches Arzteblatt, vol. 96, pp. C-2302-C-2309, December, 1999, including English language summary, (Exhibit 2)			
	A13	Parveen Kumar et al., 3 rd Edition, Clinical Medicine, pp. 369-370, Bailliere Tindall, (Exhibit 3)			
	A14 -	Jan De Jonge et al., "PRODUCTION AND CHARACTERIZATION OF BISPECIFIC SINGLE-CHAIN ANTIBODY FRAGMENTS.", Molecular Immunology, vol. 32, No. 17/18, pp. 1405-1412, 1995, (Exhibit 4)			
	A15	Jan De Jonge et al., "In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 X Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model1.", The Journal of Immunology, vol. 161, pp. 1454-1461, 1998, (Exhibit 5)			
M	A16	Matthias Mack et al., "Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3.", Proceedings of the National Academy of Science, vol. 92, pp. 7021-7025, 1995, (Exhibit 6)			
			•		
			,		
	7				
EXAMINER			DATE CONSIDERED	7	
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw					
line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					